WO2024003038 - BIFIDOBACTERIUM FOR USE IN INFLUENCING LOW-GRADE INFLAMMATION
National phase entry:
Publication Number
WO/2024/003038
Publication Date
04.01.2024
International Application No.
PCT/EP2023/067449
International Filing Date
27.06.2023
Title **
[English]
BIFIDOBACTERIUM FOR USE IN INFLUENCING LOW-GRADE INFLAMMATION
[French]
BIFIDOBACTERIUM DESTINÉ À ÊTRE UTILISÉ POUR AGIR SUR UNE INFLAMMATION DE FAIBLE AMPLEUR
Applicants **
CHR. HANSEN A/S
Inventors
ENGEL, Sara
DAMHOLT, Anders
Priority Data
22181499.9
28.06.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1937 | |
| EPO | Filing, Examination, Granting | 8159 | |
| Japan | Filing, Examination, Granting | 2078 | |
| South Korea | Filing, Examination, Granting | 1865 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,779
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention generally relates to human therapeutic effects of Bifidobacterium adolescentis, and particularly alleviating of low-grade inflammation in an elderly population.[French]
La présente invention concerne de manière générale les effets thérapeutiques chez l'être humain de Bifidobacterium adolescentis, et en particulier pour soulager une inflammation de faible ampleur chez une population âgée.